D57.2 - Sickle Cell Disease: Causes & Treatment
D57.2 is the ICD-10 code for sickle-cell disease with double heterozygosity. It is an inherited disorder affecting red blood cells and haemoglobin.
Things worth knowing about "D57.2"
D57.2 is the ICD-10 code for sickle-cell disease with double heterozygosity. It is an inherited disorder affecting red blood cells and haemoglobin.
What is D57.2?
D57.2 is a diagnostic code from the International Classification of Diseases (ICD-10) that refers to sickle-cell disease with double heterozygosity. This code covers forms of sickle-cell disease in which a person has inherited one sickle-cell gene (HbS) together with another abnormal haemoglobin gene, such as HbC or a β-thalassaemia gene. The result is a clinically significant haemoglobinopathy (inherited disorder of haemoglobin).
Causes and Genetic Background
Sickle-cell disease is caused by mutations in the β-globin gene on chromosome 11. In D57.2, the person carries two different abnormal genes -- a condition called compound heterozygosity. The most common subtypes include:
- HbSC disease: a combination of HbS and HbC haemoglobin
- HbS/β-thalassaemia: a combination of HbS and a β-thalassaemia gene
Both parents must be carriers of one of the affected genes. The disease follows an autosomal recessive inheritance pattern.
Symptoms
Symptoms are similar to those of classic sickle-cell anaemia (HbSS) but are often somewhat milder. Typical symptoms include:
- Vaso-occlusive pain crises: sudden, severe pain in bones, joints, chest, and abdomen
- Anaemia: fatigue, paleness, dizziness
- Enlarged spleen (splenomegaly), especially in HbSC disease
- Increased infection risk due to reduced spleen function
- Acute chest syndrome: chest pain, cough, fever, and shortness of breath
- Stroke caused by blood vessel blockages
- Retinopathy: damage to the retina, particularly common in HbSC
Diagnosis
Diagnosis is established through the following investigations:
- Haemoglobin electrophoresis or HPLC (High Performance Liquid Chromatography): to identify the specific haemoglobin types
- Full blood count: to detect anaemia and abnormal red blood cells
- Genetic testing: to confirm the mutation in the β-globin gene
- Newborn screening: performed routinely in many countries
Treatment
For most patients, there is currently no widely available cure. Treatment focuses on relieving symptoms and preventing complications:
Medical Therapy
- Hydroxycarbamide (hydroxyurea): increases fetal haemoglobin (HbF) production and reduces the frequency of pain crises
- Pain relief: NSAIDs or opioids depending on severity during crises
- Antibiotic prophylaxis: particularly penicillin in children to prevent infections
- Folic acid supplementation: to support red blood cell production
Blood Transfusions
Regular exchange transfusions may be used in severe cases to reduce the proportion of sickle haemoglobin in the blood.
Stem Cell Transplantation
Allogeneic haematopoietic stem cell transplantation is currently the only potentially curative treatment, but it is limited to selected patients who have a suitable donor.
Gene Therapy
Newer gene therapy approaches are under clinical development or regulatory review and may offer a curative option for a broader group of patients in the future.
Prognosis and Outlook
Patients with D57.2, particularly those with HbSC disease, often have a milder clinical course compared to patients with HbSS. However, serious complications can still occur. Regular specialist follow-up, care in specialised centres, and consistent preventive measures are key to maintaining a good quality of life.
References
- World Health Organization (WHO): Sickle-cell disease and other haemoglobin disorders. Fact Sheet. Geneva: WHO, 2011.
- Rees DC, Williams TN, Gladwin MT: Sickle-cell disease. The Lancet. 2010;376(9757):2018-2031.
- National Heart, Lung, and Blood Institute (NHLBI): Evidence-Based Management of Sickle Cell Disease. Expert Panel Report. U.S. Department of Health and Human Services, 2014.
Building Blocks for a Healthy Life
As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.
Verwandte Produkte
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.